Filtered By:
Drug: Diovan
This page shows you your search results in order of relevance. This is page number 5.
Order by Relevance | Date
Total 78 results found since Jan 2013.
Sacubitril-Valsartan versus Standard Anti-Hypertensives in Left Ventricular Assist Device Patients
Hypertension is a common comorbidity affecting patients with left ventricular assist devices (LVAD). Left uncontrolled, it may lead to a decrease in LVAD support and increase the risk for stroke. The ISHLT defines hypertension in LVAD patients as a mean arterial pressure (MAP) of> 90 mmHg and recommends aggressive management utilizing standard heart failure medications. Sacubitril-valsartan (Entresto ®) is an angiotension II blocker-neprilysin inhibitor with potent anti-hypertensive effects approved for the treatment of heart failure with a reduced ejection fraction.
Source: Journal of Cardiac Failure - August 1, 2018 Category: Cardiology Authors: Erika Nicolsen, Lisa Curran, Stephanie Dixon, Molly Reece, Sarah Herbert, Amy Clegg, Michael Tillery, Daniel Bensimhon, Dalton McLean Tags: 070 Source Type: research
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial
Publication date: 24–30 August 2019Source: The Lancet, Volume 394, Issue 10199Author(s): Gholamreza Roshandel, Masoud Khoshnia, Hossein Poustchi, Karla Hemming, Farin Kamangar, Abdolsamad Gharavi, Mohammad Reza Ostovaneh, Alireza Nateghi, Masoud Majed, Behrooz Navabakhsh, Shahin Merat, Akram Pourshams, Mahdi Nalini, Fatemeh Malekzadeh, Masoumeh Sadeghi, Noushin Mohammadifard, Nizal Sarrafzadegan, Mohammad Naemi-Tabiei, Abdolreza Fazel, Paul BrennanSummaryBackgroundA fixed-dose combination therapy (polypill strategy) has been proposed as an approach to reduce the burden of cardiovascular disease, especially in low-income ...
Source: The Lancet - August 23, 2019 Category: General Medicine Source Type: research
Sacubitril/Valsartan Improves Left Atrial and Left Atrial Appendage Function in Patients With Atrial Fibrillation and in Pressure Overload-Induced Mice
LCZ696 (sacubitril/valsartan) is an angiotensin receptor-neprilysin inhibitor and has shown beneficial effects in patients with heart failure. However, whether LCZ696 protects against left atrial (LA) and LA appendage (LAA) dysfunction is still unclear. The present study aimed to assess the efficacy of LCZ696 for improving the function of LA and LAA. We performed both a retrospective study comparing LCZ696 with angiotensin receptor blockers (ARBs) to assess the efficacy of LCZ696 in patients with atrial fibrillation and an animal study in a mouse model with pressure overload. LA peak systolic strain, LAA emptying flow velo...
Source: Frontiers in Pharmacology - October 28, 2019 Category: Drugs & Pharmacology Source Type: research
Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis.
CONCLUSIONS: ACEi/ARB and MRA can be safely used in CA, provided that no contraindications are present, treatment is started at a low dose and slowly up-titrated, and patients are monitored quite closely. Beta-blocker therapy is less tolerated in patients with AL amyloidosis and/or worse haemodynamic function.
PMID: 32475765 [PubMed - as supplied by publisher]
Source: European Journal of Internal Medicine - May 27, 2020 Category: Internal Medicine Authors: Aimo A, Vergaro G, Castiglione V, Rapezzi C, Emdin M Tags: Eur J Intern Med Source Type: research
A Contemporary Approach to Hypertensive Cardiomyopathy: Reversing Left Ventricular Hypertrophy
AbstractPurpose of ReviewTo highlight pharmacological and non-pharmacological approaches to reversing hypertensive left ventricular hypertrophy (LVH). We identify high-risk phenotypes that may benefit from aggressive blood pressure (BP) management to prevent incident outcomes such as the development of atherosclerotic cardiovascular disease, stroke, and heart failure.Recent FindingsLVH is a modifiable risk factor. Intensive BP lowering (systolic BP< 120 mmHg) induces greater regression of electrocardiographic LVH than standard BP targets. The optimal agents for inducing LVH regression include renin–angiotensinogen...
Source: Current Hypertension Reports - September 4, 2020 Category: Primary Care Source Type: research
Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension.
CONCLUSION: In mostly elderly high-risk hypertensive patients with type 2 diabetes mellitus participating in the VALUE trial, achieving more frequently BP <140/90 mmHg showed a marked protective effect on overall and all cause-specific cardiovascular outcomes. This was not the case for a more frequent achievement of the more intensive BP target, i.e. <130/80 mmHg.
PMID: 33403886 [PubMed - as supplied by publisher]
Source: Blood Pressure - January 8, 2021 Category: Hematology Tags: Blood Press Source Type: research
IJERPH, Vol. 19, Pages 2089: ARNI in HFrEF & mdash;One-Centre Experience in the Era before the 2021 ESC HF Recommendations
Conclusions: Our current positive experience in ARNI therapy is limited to extremely severe patients with HFrEF. Regardless of the more advanced HF and HF comorbidities, the patients treated with ARNI presented similar mortality and rehospitalizations as the patients treated by standard therapy.
Source: International Journal of Environmental Research and Public Health - February 13, 2022 Category: Environmental Health Authors: Rafa ł Niemiec Irmina Morawska Maria Stec Wiktoria Kuczmik Andrzej S. Swinarew Arkadiusz Stanula Katarzyna Mizia-Stec Tags: Article Source Type: research
Cardiopulmonary exercise test-based assessment of the effects of sacubitril/valsartan on the blood pressure response to exercise in patients with acute myocardial infarction during hospitalization
CONCLUSION: Treatment with S/V was able to reduce the exercise blood pressure in patients with AMI during hospitalization, but did not significantly improve the VO2 peak, VE/VCO2 slope, or exercise tolerance.PMID:35315303 | DOI:10.1080/10641963.2022.2055765
Source: Clinical and Experimental Hypertension - March 22, 2022 Category: Cardiology Authors: Chun-Mei Zeng Yan-Mei Zhao Yi-Yi Li Zhi-Hai Lin Ping Li Ying Feng Jian-Ping Tan Kai-Fang Pang Source Type: research
Cost Effectiveness of the First ‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting
ConclusionsThis was the first study to evaluate the cost effectiveness of sacubitril/valsartan in the treatment of hypertension. Sacubitril/valsartan compares favorably with allisartan isoproxil and valsartan in the Chinese setting, which is mainly due to its higher efficacy resulting in fewer cardiovascular events and ultimately less related mortality over time. The results could inform deliberations regarding reimbursement and access to this treatment in China and may provide reference for facilitating more reasonable and efficient allocation of limited resources in such low- and middle-income countries.
Source: PharmacoEconomics - September 8, 2022 Category: Health Management Source Type: research
Haemodynamic Effects of Sacubitril/Valsartan Initiation in Outpatients with Chronic Heart Failure
ConclusionThe vasodilative effects of S/V result in immediate reductions in SVRI, SBP, SV and CI. However, S/V induces reverse cardiac remodelling, which is apparent shortly after treatment initiation and leads to improvements of clinical, functional, echocardiographic, laboratory and haemodynamic variables.
Source: American Journal of Cardiovascular Drugs - September 22, 2022 Category: Cardiology Source Type: research
Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension
RARITAN, NJ, November 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Idorsia Ltd, today announced results from the Phase 3 PRECISION study, which found aprocitentan, an investigational, novel dual endothelin receptor antagonist (ERA), significantly reduced blood pressure (BP) and maintained the effect for up to 48 weeks when added to standardized combination background antihypertensive therapy in patients with difficult-to-control hypertension (sometimes referred to as resistant hypertension). These data were presented as a Late-Breaking Science presentation during the Amer...
Source: Johnson and Johnson - November 7, 2022 Category: Pharmaceuticals Source Type: news
The initial timing and dosage pattern of sacubitril/valsartan in patients with acute myocardial infarction undergoing percutaneous coronary intervention
CONCLUSIONS: Early use or high dosage of sacubitril/valsartan medication is associated with an improvement in clinical outcome. The low dose of sacubitril/valsartan is well tolerated and may be an acceptable alternative strategy.PMID:36990878 | DOI:10.1016/j.ejim.2023.03.019
Source: European Journal of Internal Medicine - March 29, 2023 Category: Internal Medicine Authors: Jun Gu Yue Wang Chang-Qian Wang Jun-Feng Zhang Source Type: research
